Detalhe da pesquisa
1.
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1.
N Engl J Med
; 384(13): 1216-1226, 2021 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33789010
2.
ePHex: a phase 3, double-blind, placebo-controlled, randomized study to evaluate long-term efficacy and safety of Oxalobacter formigenes in patients with primary hyperoxaluria.
Pediatr Nephrol
; 38(2): 403-415, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35552824
3.
Safety, pharmacodynamics, and exposure-response modeling results from a first-in-human phase 1 study of nedosiran (PHYOX1) in primary hyperoxaluria.
Kidney Int
; 101(3): 626-634, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34481803
4.
Early clinical course of biopsy-proven IgA vasculitis nephritis.
BMC Pediatr
; 22(1): 570, 2022 10 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36195856
5.
Age-associated decrease in de novo donor-specific antibodies in renal transplant recipients reflects changing humoral immunity.
Immun Ageing
; 16: 9, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31168309
6.
A complicated case of atypical hemolytic uremic syndrome with frequent relapses under eculizumab.
Pediatr Nephrol
; 30(6): 1039-42, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25752761
7.
Nedosiran Safety and Efficacy in PH1: Interim Analysis of PHYOX3.
Kidney Int Rep
; 9(5): 1387-1396, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38707801
8.
Nedosiran in primary hyperoxaluria subtype 3: results from a phase I, single-dose study (PHYOX4).
Urolithiasis
; 51(1): 80, 2023 Apr 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-37118061
9.
Severe neurological outcomes after very early bilateral nephrectomies in patients with autosomal recessive polycystic kidney disease (ARPKD).
Sci Rep
; 10(1): 16025, 2020 09 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-32994492
10.
C3-Glomerulopathy Autoantibodies Mediate Distinct Effects on Complement C3- and C5-Convertases.
Front Immunol
; 10: 1030, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31214159
11.
Correction to: Nedosiran in primary hyperoxaluria subtype 3: results from a phase I, single-dose study (PHYOX4).
Urolithiasis
; 51(1): 85, 2023 Jun 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37273015